newsfilter
← Latest News
GlobeNewswire·

Neoleukin Therapeutics Announces Oral Presentation at IDWeek 2021 of Data Demonstrating that NL-CVX1, a Computationally Designed De Novo Protein, Can Block Infection by SARS-CoV-2 Viral Variants of Concern

– Single intranasal dose of NL-CVX1 in mice prevents infection by multiple variants of SARS-CoV-2 – – Transgenic mice that are protected from disease by NL-CVX1 remain resistant to rechallenge after one month – SEATTLE, Sept. 29, 2021